Drug antibody firm collaborates on Innovate UK project
ANTIBODY drug company Glythera has been awarded a grant from the government’s innovation agency Innovate UK to develop
Glythera won the £248,000 funding as part of a team including bioscience firm GlycoSeLect and the Centre for Process Innovation in Redcar.
The funding will be used to help develop the next generation of biological therapeutics.
The early stage feasibility study award will support the growth of drug development pathways using Glythera’s PermaCarbTM technology platform.
The firm has previously proven that glycan compounds can improve drug bioavailability, which has broad applications in drug discovery, development and production, especially in the high-value biobetter & biosimilar markets.
Dr Dave Simpson, chief executive of Glythera, said: “The funding from Innovate UK will further enhance Glythera’s established PermaCarbTM drug development technology through the expansion of GlycoSelect’s analytical platform and fundamentally remove the analytical bottlenecks typically associated with development and manufacture of complex biotherapeutics.
“This combined technology offering will allow Glythera to drive the industry’s ability to develop novel drugs from multiple product classes which can be administered at lower doses and / or reduced frequency. This is an important step in the advancement of next generation biological medicines and could lead to improved patient responses.”
Robert Dunne, chief executive of GlycoSeLect, said: “GLycoSeLect is excited about this collaboration with two important partners which will help to further validate our RPL technology as a first pass, efficient and cost-effective analytical tool for the characterisation of biotherapeutics.”
Dr Chris Dowle, director of Biologics at CPI, said: “CPI is very pleased to be a partner in this project and helping two SMEs to develop their business and achieve success. The project is in line with our Biologics strategy to support the commercialisation of new process and analytical technologies for current and next generation biologics”
